Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409817 | 0.92 | S1PR1 (0.45) | S1PR1S1PR3 | |
| SCHEMBL558362 | 0.89 | S1PR1 (0.65) | S1PR1S1PR3S1PR5 | |
| SCHEMBL18901353 | 0.89 | S1PR1 (0.45) | S1PR1S1PR3 | |
| SCHEMBL558108 | 0.88 | S1PR1 (0.56) | S1PR1S1PR3S1PR5 | |
| SCHEMBL558359 | 0.88 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL409518 | 0.86 | S1PR1 (0.62) | S1PR1S1PR3 | |
| SCHEMBL557869 | 0.85 | S1PR1 (0.69) | S1PR1S1PR3S1PR5 | |
| SCHEMBL536614 | 0.84 | S1PR1 (0.62) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2774014 | 0.83 | S1PR1 (0.57) | S1PR1S1PR3 | |
| SCHEMBL410963 | 0.83 | S1PR1 (0.65) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2010112461-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | S1PR1 448/4885S1PR3 310/4885S1PR5 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.